Atagabalin
Atagabalin
| obere ụdị nke | chemical compound  |
|---|---|
| usoro kemịkalụ | C₁₀H₁₉NO₂ |
| canonical SMILES | CC1CC(CC1C)(CC(=O)O)CN |
| isomeric SMILES | C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN |
Atagabalin (PD-0200,390) bụ ọgwụ nke Pfizer mepụtara site na afo nwela onwa ma nwee njikọ na gabapentin, nke na-ejikọta ya na ọwa calcium α2δ (1 na 2).[1] Ọ nọ na mmepe dị ka ọgwụgwọ maka ehighị ụra nke ọma, mana a kwụsịrị ya mgbe nsonaazụ nnwale na-adịghị mma gasịrị.[2][3][4]
Hụkwa
dezie- 4-Methylpregabalin
- Gabapentin enacarbil
- PD-217,014
Ntụaka
dezie- ↑ (January 2010) "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters 20 (2): 461–4. DOI:10.1016/j.bmcl.2009.11.118. PMID 20005103.
- ↑ (August 2009) "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology 68 (2): 174–80. DOI:10.1111/j.1365-2125.2009.03444.x. PMID 19694735.
- ↑ (May 2011) "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research 1401: 1–9. DOI:10.1016/j.brainres.2011.05.025. PMID 21664606.
- ↑ (June 2011) "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research 28 (10): 2610–27. DOI:10.1007/s11095-011-0490-x. PMID 21681607.